Lung Adenocarcinoma

In addition, SGO2 compromised the cisplatin (CDDP) sensitivity of LUAD in vitro and in vivo...Silencing SGO2 with OA improved LUAD chemo sensitivity. Our work highlights the potential of SGO2 as a target for therapeutic intervention and OA as a food-bioactive compound for LUAD treatment.

Data suggest that drugs used in the treatment of MS can modify ACE2 expression; specifically, fingolimod reduces ACE2 expression and may have a protective role against SARS-CoV-2 infection.

Subtyping based on single-cell derived marker genes and multi-level analyses provide a comprehensive understanding of LUAD biology. The distinct features of C1 and C2 subtypes highlight the need for tailored therapies. The eight-gene signature may serve as a novel prognostic, diagnostic, and therapeutic indicator.

HNF4α also promotes resistance to KRAS inhibition by increasing nuclear factor erythroid 2-related factor 2 (NRF2) activity. These findings may advance therapeutic avenues in IMA.

Experimentally, KRASQ61R mutation led to KRAS exon 3 skipping, which in turn could be rescued by expression of U2AF1I24T. Our findings provide evidence that splicing factor mutations can rescue splicing defects caused by oncogenic mutations in a dynamic process of cascading selection.

Nearly 7% of EGFR mutations in NSCLC patients were compound mutations, which is comparable to previous reports. The presence of multiple mutations, particularly those involving T790M , may be associated with potential resistance to first-line EGFR -TKIs. We describe a triple mutation involving del19 + G719X + S768I , which represents an uncommon scenario.

Findings on EGFR mutations were consistent with the national and international literature. However, PD-L1 expression rates were higher than those typically reported in Brazilian studies, highlighting regional variation in biomarker prevalence.

The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.

In vivo, 5Z7 plus cisplatin suppressed resistant tumor growth without notable organ toxicity. This study establishes TAK1 as a key hub in cisplatin resistance and shows that 5Z7 reverses resistance by targeting TAK1 to coordinately regulate NF-κB/p53 signaling, providing a foundation for potential clinical translation.

The prognosis of patients with peripheral SCC was poorer than that of patients with adenocarcinoma. Possible contributing factors included the tendency to avoid anatomical resection, a high rate of death from other causes, and the high malignancy of the tumors.

P1/2, N=77, Suspended, University of California, Davis | Trial completion date: Jan 2030 --> Jan 2034 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2030

Its direct tumor-suppressive function remains to be determined in future mechanistic studies. These findings provide a basis for further mechanistic studies and future validation of CD53-related diagnostic, prognostic, and therapeutic hypotheses in LUAD.